OncLive TV

Yongfeng He, PhD, discusses how the presence of the GTF2I L424H mutation in thymic epithelial cells induced thymic tumors in mouse models.

Amanda Cass, PharmD, BCPS, BCOP, discusses strategies to manage the diarrhea that may occur as an adverse effect in patients treated with EGFR TKIs.

Emily Skotte, MSN, discusses common ways to manage the rashes that may occur as adverse effects in patients treated with EGFR TKIs.

Giuseppe Giaccone, MD, PhD, discusses recent data with investigational therapies for patients with thymic cancer.

Giuseppe Giaconne, MD, PhD, discusses why thymic cancers can be difficult to classify histologically, so the actual incidence is unclear.

Giuseppe Giaconne, MD, PhD, and Yongfeng He, PhD, discuss how cancers of the thymus, a small organ located in the mediastinum above the heart, are uncommon and understudied.

Adana A.M. Llanos, PhD, MPH, discusses the role of social and biological determinants on cancer risk.

Gordana Vunjak-Novakovic, PhD, BS, MS, discusses the clinical need for personalizing cancer care.

Andrea Baccarelli, MD, PhD, discusses the effect of environmental factors on cancer diagnoses.

Ross Camidge, MD, PhD, discusses toxicities observed with sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer.

Neil D. Gross, MD, FACS, discusses the investigation of cemiplimab in cutaneous squamous cell carcinoma.

Rahul Aggarwal, MD, discusses the rationale for investigating androgen deprivation therapy intensification in biochemically relapsed prostate cancer.

Barry Paul, MD, discusses the emerging benefits of integrating CAR T-cell therapy into treatment paradigms for patients with relapsed/refractory multiple myeloma.

Amit Jain, MD, discusses the benefit of CDK7 inhibitors in hormone receptor–positive breast cancers.

Farrukh Awan, MD, discusses the evolution of treating frontline chronic lymphocytic leukemia.

Shilpa Gupta, MD, discusses the addition of cabozantinib to avelumab in locally advanced or metastatic urothelial cancer.

Jeff Yorio, MD, discusses adverse effects associated with targeted agents and combinations in BRAF-mutated melanoma.

John O. Mascarenhas, MD, discusses the potential clinical significance of pacritinib in patients with myelofibrosis.

Rory Shallis, MD, discusses the investigation of uproleselan in acute myeloid leukemia.

Ghassan K. Abou-Alfa, MD, discusses the analysis of disease and patient factors to inform clinical decisions in hepatocellular carcinoma.

Laura Goff, MD, discusses how to consider clinical trial information to inform treatment decisions in patients with hepatocellular carcinoma.

Beth Y. Karlan, MD, discusses the current landscape of research investigating the efficacy of PARP inhibitor combination therapies for the treatment of patients with ovarian cancer.

Wade T. Iams, MD, discusses the potential for providing small cell lung cancer subtyping in clinical practice.

Shebli Atrash, MD, discusses the development and current use of BCMA-targeted antibody-drug conjugates and CAR T-cell therapies for the treatment of patients with multiple myeloma.

Wenxin Xu, MD, discusses future considerations for the treatment of patients with kidney cancer. 

Andre H. Goy, MD, discusses clinical trial vs real-world treatments in patients with mantle cell lymphoma.

Sheena Bhalla, MD, discusses the need for improved understanding of EGFR exon 20 insertion mutations in the development of non–small cell lung cancer treatment.

John H. Strickler, MD, discusses the benefit of combining tucatinib with trastuzumab in HER2-positive metastatic colorectal cancer.

Neal Shore MD, FACS, discusses future clinical research focuses in prostate cancer.

Christine Ryan, MD, discusses the significance of data for ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.